{"schema_version":"1.0","type":"article","title":"核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.md","lang":"zh-Hant","date":"2026-08-24","publish_at":"2026-08-24T08:00:00+08:00","updated_at":"2026-08-24","category":"商業分析系列","topic":"BD / 授權","tags":["Curium","Lantheus","核藥","放射性藥物","診療一體化","PSMA","PYLARIFY","Pluvicto","併購","長佳智能","商之器"],"summary":"6 月官網追蹤的 Curium–Lantheus 70 億美元收購傳聞，已在 8 月 3 日推進為最終合併協議：每股 102.50 美元現金加最高 12 美元 CVR，總交易價值最高約 80 億美元。真正被整合的是核素、製造、配送、診斷、治療與美國院端網絡。","key_points":[],"facts":[],"sections":["00｜從 70 億美元傳聞，走到最高 80 億美元最終協議","01｜Curium 缺的是美國終端，Lantheus 缺的是上游與治療端","02｜核藥為什麼特殊？因為半衰期決定商業模式","03｜診療一體化，才是核藥最有價值的商業閉環","04｜競爭規則改寫：從單點管線，走向全鏈條整合","05｜台灣直接核藥個股少，但影像與核醫基礎設施值得觀察","結語｜核藥競爭，已經不是一條管線的競爭","參考資料"],"references":[{"title":"[Facebook","source":"藥時事原始公開長文，2026-08-24]","date":"","url":"https://www.facebook.com/61568446257142/posts/122183498798614875"},{"title":"[Lantheus","source":"Curium Announces Definitive Agreement to Merge with Lantheus, 2026-08-03]","date":"","url":"https://investor.lantheus.com/node/17091"},{"title":"[Curium","source":"How we work：全球製造與配送網絡]","date":"","url":"https://www.curiumpharma.com/about/how-we-work/"},{"title":"[ClinicalTrials.gov","source":"ECLIPSE Phase 3, NCT05204927]","date":"","url":"https://clinicaltrials.gov/study/NCT05204927"},{"title":"[Lantheus","source":"FDA Approval of PYLARIFY TruVu, 2026-03-06]","date":"","url":"https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-fda-approval-pylarify-truvutm-piflufolastat-f"},{"title":"[Lantheus","source":"2025 shareholder materials：Neuraceq 與產品組合]","date":"","url":"https://investor.lantheus.com/static-files/65cb003c-d33a-441c-b1f7-c6ea7768da2a"},{"title":"[Novartis","source":"Full-year 2025 results：Pluvicto sales]","date":"","url":"https://www.novartis.com/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025"},{"title":"[Eli Lilly","source":"Lilly Completes Acquisition of POINT Biopharma]","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-point-biopharma"},{"title":"[臺灣新吉美碩","source":"公司簡介與核醫藥品製造配送]","date":"","url":"https://www.gmstw.com.tw/about.php"},{"title":"[TFDA","source":"AI／機器學習醫療器材許可證資料]","date":"","url":"https://www.fda.gov.tw/tc/includes/GetFile.ashx?id=f639083041331900606&type=1"},{"title":"[商之器","source":"PACS、RIS、DICOM 與 AI 醫療影像服務]","date":"","url":"https://www.ebmtech.com/tw/services"}],"images":[{"alt":"圖 1｜Curium 的核素、製造、配送與治療端，和 Lantheus 的美國診斷產品與醫院網絡形成互補","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-01.webp"},{"alt":"圖 2｜核藥從同位素生產、標記、品管、屏蔽配送到院端使用，每一步都受到半衰期限制","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-02.webp"},{"alt":"圖 3｜Find、Fight、Follow：先用 PSMA PET 找到患者，再以靶向核藥治療，最後持續影像追蹤","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-03.webp"},{"alt":"圖 4｜核藥併購邏輯從購買單一管線，升級為整合同位素、製造、配送、診斷、治療與院端通路","url":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-04.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-24）。核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額。https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-24-curium-lantheus-definitive-merger-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}